MTOR and acute lymphoblastic leukemia: For example, the reactivation of p53 by Nutlin-3 and the inhibition of AKT/mTOR by tanshinone IIA exhibit a synergetic antileukemia effect with Imatinib in Philadelphia-positive ALL [83].